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Abstract
Background: Antiretroviral drug resistance is becoming increasingly common with the expansion of human
immunodeficiency virus (HIV) treatment programmes in high prevalence settings. Genotypic resistance testing
could have benefit in guiding individual-level treatment decisions but successful models for delivering resistance
testing in low- and middle-income countries have not been reported.
Methods: An HIV Treatment Failure Clinic model was implemented within a large primary health care HIV
treatment programme in northern KwaZulu-Natal, South Africa. Genotypic resistance testing was offered to adults
(≥16 years) with virological failure on first-line antiretroviral therapy (one viral load >1000 copies/ml after at least 12
months on a standard first-line regimen). A genotypic resistance test report was generated with treatment
recommendations from a specialist HIV clinician and sent to medical officers at the clinics who were responsible for
patient management. A quantitative process evaluation was conducted to determine how the model was
implemented and to provide feedback regarding barriers and challenges to delivery.
Results: A total of 508 specimens were submitted for genotyping between 8 April 2011 and 31 January 2013; in
438 cases (86.2%) a complete genotype report with recommendations from the specialist clinician was sent to the
medical officer. The median turnaround time from specimen collection to receipt of final report was 18 days
(interquartile range (IQR) 13–29). In 114 (26.0%) cases the recommended treatment differed from what would be
given in the absence of drug resistance testing. In the majority of cases (n = 315, 71.9%), the subsequent treatment
prescribed was in line with the recommendations of the report.
Conclusions: Genotypic resistance testing was successfully implemented in this large primary health care HIV
programme and the system functioned well enough for the results to influence clinical management decisions in
real time. Further research will explore the impact and cost-effectiveness of different implementation models in
different settings.
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(health care), Capacity building
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Background
The rapid expansion of public health human immunodefi-
ciency virus (HIV) programmes in the past decade has led
to over eight million people accessing antiretroviral ther-
apy (ART) in low- and middle-income countries [1]. Many
challenges remain as we transition from an emergency re-
sponse to long-term, sustainable strategies [2,3], one of
which is the prevention and management of antiretroviral
drug resistance [4].
The World Health Organization (WHO) global strat-
egy on drug resistance relies on surveillance of trans-
mitted and acquired resistance, with survey results
informing treatment policies [5,6]. In time, the detec-
tion of drug resistance for individual case management
might become more important as the public health ap-
proach to ART delivery becomes less effective and as
the case mix becomes more complex. In South Africa,
the national antiretroviral treatment guidelines now in-
corporate recommendations for genotypic resistance
testing in certain situations (e.g. failure of second-line
ART in adults and children) [7]. The Southern African
HIV Clinicians Society guidelines go further in recom-
mending genotypic resistance testing at time of first-
line ART failure in adults [8].
The Southern African Treatment and Resistance
Network (SATuRN) has developed models for imple-
mentation of antiretroviral drug resistance testing
within HIV programmes, with the aim of integrating
clinical care, training, surveillance and research [9,10].
Different implementation models have so far been in-
troduced within the national programme in Botswana
and in the Free State province of South Africa. Here we
describe an HIV Treatment Failure Clinic (HIV-TFC)
model developed for a primary health care programme in
rural KwaZulu-Natal. We have reported clinical outcomes
for adults on ART in this programme that are broadly
similar to other public sector programmes in South Africa
[11-13]. However, the programme’s systems for detection
and management of ART failure have been relatively inef-
fective, to the extent that, of the 20 000 adults enrolled on
ART by the end of 2010, fewer than 100 (0.5%) had been
switched to second-line ART regimens despite virological
failure rates comparable to other programmes in the re-
gion [14]. The implementation of antiretroviral drug re-
sistance testing as part of a research study provided an
opportunity to address the backlog of treatment failure
cases and provide focused training to staff on the detec-
tion and management of treatment failure, whilst simul-
taneously facilitating drug resistance surveillance and
research. We have reported the detailed results from the
antiretroviral drug resistance testing for adults separately
[15]. Here we focus on a quantitative process evaluation of
the system and a discussion of the main achievements and
challenges of implementation.
Methods
Setting
The Hlabisa HIV Treatment and Care Programme has
since August 2004 provided comprehensive HIV services at
17 primary health care (PHC) clinics and one district hos-
pital in the predominantly rural Hlabisa sub-district (1430
km2) in northern KwaZulu-Natal [11,12]. The programme
is co-ordinated by the local Department of Health with sup-
port from the Africa Centre for Health and Population
Studies (Africa Centre, www.africacentre.ac.za). HIV treat-
ment and care is delivered largely by nurses and counsel-
lors, with medical officers visiting clinics on a weekly or
fortnightly basis. The programme adheres to national anti-
retroviral treatment guidelines and routine laboratory
monitoring (CD4+ cell count and HIV-1 viral load) is per-
formed at the National Health Laboratory Service (NHLS)
laboratory situated at the district hospital. The scale-up of
antiretroviral therapy has been rapid such that, by the end
of 2012, more than 50,000 individuals had been enrolled
in HIV care and 25,000 individuals had initiated ART.
Participants
HIV-infected adults (≥16 years) with virological failure on
first-line (non-nucleoside reverse transcriptase inhibitor
(NNRTI)-based) ART were eligible for the intervention.
Virological failure was defined for this study as one viral
load >1000 copies/ml after at least 12 months of first-line
ART. The intervention was initially piloted from December
2010 and was fully operational by April 2011. Individ-
uals were recruited at all 17 PHC clinics. We implemented
the HIV-TFC model in two different strategies at the clinic
level, with the aim of allowing future comparison of pa-
tient outcomes and costs. The first involved patients being
enrolled for resistance testing by the medical officer dur-
ing routine clinic visits, with referral to members of the
multidisciplinary team such as the social worker, the
psychologist or the dietician as appropriate, on a case-by-
case basis. The second strategy adopted a treatment failure
support camp approach, whereby eligible individuals were
identified from the programme database; individuals were
then invited in groups of 10 to 15 to attend their normal
clinic on a specific day and each participant was reviewed
by a social worker and a community adherence educator
in addition to the medical officer, in order to specifically
address adherence issues, with referral to other multidis-
ciplinary team members on the same day if required.
Intervention
The intervention model for incorporating resistance testing
into routine clinic management is illustrated in Figure 1. At
the initial clinic visit, the medical officer obtains written in-
formed consent for the study, performs a clinical assess-
ment and completes a standardised clinical history form. A
blood sample is collected by the medical officer at the clinic
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for HIV drug resistance genotyping and is transported
to the Africa Centre (mean distance 30km, range 2–68)
and then onwards the same day to the laboratory in
Durban (~250 km). The clinical history form is delivered to
the Africa Centre by the medical officer and these data
are anonymised and captured into a relational database
(SATuRN RegaDB) [10,16,17]. Genotypic resistance testing
is performed using the in-house SATuRN/Life Technolo-
gies method [18]. In order to keep the costs low, no viral
load was performed before drug resistance genotyping. A
genotype report is generated in the laboratory and an initial
‘plain-language’ summary is added by laboratory staff. This
initial report is then sent via email with the clinical history
form to a specialist HIV clinician, who provides a more
1 – Medical officer assesses patient with virological failure at clinic or district hospital
2 - Blood specimen and clinical history form delivered to co-ordinator at Africa Centre 
3 - Blood specimen transported to Africa Centre virology laboratory
4 - Result of genotypic resistance test sent by secure email to specialist HIV clinician 
5 - Clinical history form (anonymised) simultaneously sent by secure email to specialist HIV clinician 
6 - Final genotypic resistance test report with interpretation and management recommendations sent 
by secure email to co-ordinator at Africa Centre
7 - Final genotypic resistance test report delivered to treating medical officer(secure email and hard  
copy)
8 – Medical officer reviews patient and institutes management recommendations at clinic or district 
hospital
a (if required)-Laboratory informs co-ordinator of failed or delayed test ± requests additional 
specimen; information relayed to treating clinician
b (if required)–Medical officercommunicates by secure email for additional advice; or specialist HIV 
clinician communicates by secure email to obtain additional clinical details to assist with genotype 
interpretation
Figure 1 The HIV Treatment Failure Clinic (HIV-TFC) model.
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specific interpretation with recommendations for on-going
medical management, including antiretroviral regimen
change where appropriate. As far as possible, recommenda-
tions for second-line regimens are made in accordance with
national guidelines, with deviations suggested only when
thought to be absolutely necessary. This final report is
emailed to the medical officer and to the data curation
team for entry into the SATuRN RegaDB. The patient then
attends their normal clinic for review and treatment is
changed as appropriate. Requests for standardised second-
line regimens are approved by the pharmacists at the dis-
trict hospital whereas requests for non-standard regimens
are submitted to and approved by a provincial task team.
The model aims for a turnaround time, from collection of
clinical information and blood sample to receipt of final re-
port by the medical officer, of fewer than 30 days.
Training, education and capacity building
All medical officers involved in the delivery of HIV care at
the PHC clinics received basic training in antiretroviral
treatment failure, drug resistance and the implementation
model prior to commencement of the project. The educa-
tion and training of nurses and counsellors at the clinics
was then performed in-situ by the doctors during routine
clinic visits and continued throughout the project. Com-
munity education was facilitated by a two-day workshop
with members of the Africa Centre Community Engage-
ment Office and Community Advisory Board. Selected
clinic staff attended a drug resistance training workshop at
the Africa Centre in May 2012 to consolidate training –
this used a case-based learning approach. Key program-
matic personnel also attended the SATuRN workshops in
October 2010, October 2011 and November 2012. In
addition, a HIV & TB drug resistance case book was
launched at a workshop in March 2013 and was distributed
to all medical officers and selected clinic nurses [19].
Process evaluation
A quantitative process evaluation was conducted alongside
the implementation of the programme. The aims of this
process evaluation were to determine the extent to which
the programme was implemented according to the protocol
and to aid explanation of programme outcomes through
analysis of operational successes and failures. The key com-
ponents of the process evaluation and the data sources are
displayed in Table 1. Contemporaneous records of the pro-
cesses were maintained by the co-ordinating team at the
Africa Centre and by the laboratory. All email communica-
tion (including reports sent to and received from the spe-
cialist clinicians) was stored in secure email archives.
Medical officers updated the co-ordinating team with de-
tails of antiretroviral switches. Where no follow-up infor-
mation was available from the medical officer, clinic files
were reviewed to ascertain vital status and relevant
treatment information. All follow-up data capture was
completed by 30 April 2013, thus allowing at least three
months post-genotype for all participants.
Ethical issues
The study was approved by the Biomedical Research Ethics
Committee of the University of KwaZulu-Natal (BF052/10)
and the Health Research Committee of the KwaZulu-Natal
Department of Health (176/10). The study was also ap-
proved by the Community Advisory Board of the Africa
Centre and permission for entry into healthcare facilities
was obtained from Hlabisa Hospital. Written informed con-
sent was obtained from all participants. There was no fi-
nancial incentive or reimbursement for participation as
procedures were part of routine clinical care.
Results
Uptake of intervention
All patients approached to participate in the study ac-
cepted the offer of a resistance test. In total, 508 speci-
mens were submitted for genotyping between 8 April
2011 and 31 January 2013. Ten medical officers were
trained and actively involved in managing patients within
the treatment failure clinic system. The number of resist-
ance tests requested per medical officer varied substan-
tially, due in part to varied lengths of service within the
programme and in part to differences in doctors’ roles in
relation to the intervention: those medical officers who re-
quested resistance tests opportunistically in primary health
care clinics enrolled between 17 and 32 participants each,
whereas two medical officers who were more directly in-
volved in the treatment failure support camps enrolled
168 and 99 participants respectively. The medical officers
themselves ranged from those at an early stage of their ca-
reers (post-internship) to HIV specialists with several years
of experience in the local setting. Adult patients from all
17 PHC clinics in the Hlabisa sub-district were enrolled,
with between one and 193 specimens originating from the
different clinics.
Production of resistance reports
Of the 508 genotypes requested, 459 (90.4%) had successful
amplification and sequencing in the laboratory (Figure 2).
Of the 49 specimens that did not amplify, 25 subsequently
had a viral load measurement on the same specimen
of <1000 copies/ml. For all specimens that were success-
fully amplified, an initial laboratory report was produced.
441 of the 459 reports were emailed to one of the specialist
HIV clinicians, who returned a final report, including any
recommendations for ART regimen change, for 438 of
these cases.
Overall, the median turnaround time from specimen
collection to receipt of final report was 18 days (interquar-
tile range (IQR) 13–29). The most time-consuming step
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was the genotypic resistance testing itself, which took a
median of 12 days (IQR 7–20). Where there were substan-
tial delays in this step (> 50 days from sample date to
genotype production, n = 27), this was usually due to the
specimen requiring more than one attempt to amplify.
The median time taken by the specialist HIV clinician to
append the laboratory report with specific interpretation
and management recommendations and to send the final
report back to the medical officer was two days (IQR 1–6).
Analysis of process indicators pertaining to the clinic
versus support camp models suggested a less efficient
process of genotypic resistance test report generation for
the support camps, although in both contexts the median
overall turnaround time for report production was under
the target of 30 days (Table 2). The proportion of sam-
ples that were successfully amplified in each context
was similar.
Treatment recommendations and patient follow up
Of the 438 genotypes for which a complete resistance
report was produced, 50 (11.4%) had no major drug
resistance-associated mutations (DRAMs) and the treat-
ment recommendation in 49 of those cases was to continue
first-line ART. A standard second-line regimen included in
the national antiretroviral guidelines was recommended in
the presence of DRAMs for 365 (83.3% of total): for 324
(74.0% of total) this was the second-line regimen that
would have been prescribed in the absence of resistance
Table 1 Indicators for process evaluation
Indicator Data source Comments
Uptake of testing (by medical officer and by clinic) Study and laboratory records Numbers enrolled by medical officer and by clinic
Proportion with valid genotype result Laboratory records Excludes instances of failed amplification or sequencing
Proportion with initial laboratory report Laboratory records Genotype report generated within laboratory
Proportion sent to specialist clinician Laboratory email records Genotype report sent by email to specialist clinician
Proportion with final laboratory report Laboratory email records Final report (with specialist clinician comments) issued by laboratory
Turnaround time
(laboratory, specialist clinician, overall)
Study, laboratory and
specialist clinician records
Laboratory – time from receipt of specimen to initial
genotype result; specialist clinician – time from receipt
of initial genotype result to generation of final laboratory report
Proportion switched to second-line
regimen as recommended
Study and medical officer
records; clinic file review
Concordance with specialist clinician recommendations
Specimens submitted
N = 508
Unsuccessful
n = 49(9.6%)
VL<1000 copies/ml
n = 25
VL>1000 copies/ml
n = 24
Initial genotype report
generated
n =459(90.4%)
Report emailed tospecialist
physician
n = 441(86.8%)
Final report issued
n = 438(86.2%)
Figure 2 Flow diagram of processes involved in production of final resistance report.
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testing; whereas in 41 cases (9.4% of total), an alternative
standard second-line regimen was recommended based
on the pattern of mutations and drug history. For ex-
ample, zidovudine (AZT), lamivudine (3TC) and lopina-
vir/ritonavir (LPV/r) was recommended for patients
failing on a stavudine (d4T)-based first line regimen with
the K65R mutation, or tenofovir (TDF), 3TC and LPV/r
was recommended for a patient failing a TDF-based first
line regimen with only NNRTI resistance mutations). For
21 patients (4.8%), a non-standard second-line regimen,
consisting of second-line drugs contained within the
guidelines, was recommended: one example was three nu-
cleoside reverse-transcriptase inhibitors with LPV/r (for
reasons other than hepatitis B infection). Finally, for three
patients, a non-standard regimen containing at least one
third-line antiretroviral agent (e.g. raltegravir (RAL) or
etravirine (ETR)) was recommended.
Follow-up information was recorded for 412 participants
(94.1%). Table 3 demonstrates the concordance between re-
port recommendations and actual prescribed ART regi-
mens for participants. 312 patients (75.7%) were on
second-line ART regimens, 276 (88.5%) of these in direct
accordance with the specialist HIV clinician’s recommenda-
tions. In cases where the second-line regimen prescribed
contravened the specialist recommendations (n = 36), this
was most commonly due to contraindications to particular
antiretroviral drugs (e.g. renal impairment or anaemia) that
were not known or not documented at the time of the ini-
tial clinical assessment. As described, three resistance re-
ports included recommendation of a regimen including
one or more third-line antiretroviral, due to the presence of
multinucleoside resistance mutations (e.g. Q151M com-
plex). In all of these cases, the recommended regimen was
RAL, ETR, 3TC and LPV/r. Two of these patients received
RAL, 3TC and LPV/r (without ETR) but in the third case
the treatment switch was delayed due to severe illness and
the patient died from disseminated tuberculosis a week
after the final resistance report was produced. In 26 cases
overall (5.9%), there was no documentation of a follow-up
visit or a treatment switch.
Discussion
This paper describes our HIV-TFC model for management
of ART failure incorporating the use of genotypic resistance
testing within a PHC programme in rural KwaZulu-Natal.
With this model we have managed 508 adults with viro-
logical failure on first-line ART between April 2011 and
January 2013. The majority (76%) of those patients are now
on appropriate second-line ART regimens.
Several others (9%) have avoided inappropriate switch
to second-line therapy after genotypic evidence of sus-
ceptibility to first-line ART and have instead received in-
tensified adherence support (the effect of which can be
seen in Case example 1). Medical officers were able to
manage patients with complex antiretroviral resistance
patterns in spite of limited experience in this specialty,
due to the clarity of genotypic interpretation and input
of specialist HIV clinicians with resistance reports. This
provides some evidence of the feasibility of genotypic re-
sistance testing for patients with ART failure in a rural
and relatively resource-limited South African context.
Case example 1
A 54-year-old male was seen in July 2011 with
virological failure on a first-line regimen consisting of
stavudine (d4T), lamivudine (3TC) and efavirenz (EFV).
He had commenced treatment in November 2009 with
WHO clinical stage 3 (concurrent pulmonary TB) and
baseline CD4+ cell count of 172 cells/μL. There was no
evidence of virological suppression after 10 months of
treatment and, after intensive adherence counselling,
viral load remained elevated at 14 months (Figure 3).
Objective assessment suggested good adherence and he
had been on time for each monthly clinic visit and
pharmacy refill. His wife was also on ART and had full
virological suppression and he reported that they
supported each other with treatment. He did, however,
disclose use of over-the-counter ‘immune boosters’.
Genotypic resistance test demonstrated no specific
Table 2 Process indicators: production of resistance report
Genotype
generation*
Laboratory
report†
Specialist
recommendations‡
Total report
turnaround
time§
All
samples
Median 12 1 2 18
IQR 7-20 0-3 1-6 13-29
Range 0-151 0-61 0-24 2-154
Clinic
Median 12 1 2 16
IQR 8-19 0-3 1-5 13-28
Range 0-151 0-61 0-24 4-154
Support
camp
Median 15 1 4 25
IQR 7-23 0-2 2-7 13-29
Range 0-144 0-47 0-17 2-153
IQR, interquartile range.
*Time from specimen collection to generation of initial genotype report.
†Time from generation of initial genotype report to sending report to
specialist clinician.
‡Time from sending of laboratory report to specialist clinician to receipt of
final report by medical officer.
§Time from initial specimen collection to receipt of final report by
medical officer.
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mutations (i.e. the predominant viral strain was wild
type). He was maintained on the same regimen (d4T/
3TC/EFV) and received further intensive adherence
support and counselling, with particular focus on the
benefits of ART and the risks of using non-prescribed
medication. Six months later, viral load was suppressed
(<40 copies/ml) and this was maintained <400 copies/
ml after a further 12 months, suggesting sustained
improvement in adherence to ART.
Overall, we found that most participants harboured HIV
strains with at least one drug resistance-associated muta-
tion, although in keeping with other studies around 10%
had no evidence of drug resistance [20-23]. In around one
in four patients overall (114/438, 26.0%), the results of
genotypic resistance testing significantly influenced
clinical management, either by allowing continuation of
the first-line regimen or by informing the selection of an
appropriate second-line regimen that was different to the
regimen that would have been recommended in the ab-
sence of genotypic resistance testing (see Case example 2).
Economic models have suggested that, in the South African
context, resistance testing would have important clinical
impacts and be cost-effective in adults at first-line ART
failure [24]. The proportion with wild type genotype re-
ported here (11%) is close to the threshold at which re-
sistance testing would be very cost-effective according
to one model [24]. However, determining the true clin-
ical impact and cost-effectiveness of resistance testing
in low-income and middle-income settings will require
well-designed clinical trials.
Case example 2
A 33-year-old female was seen in July 2012 with
virological failure on a first-line regimen of stavudine
Table 3 Specialist recommendations and follow-up outcomes
Specialist
recommendation
n Regimen prescribed
matched regimen
recommended by specialist
Regimen prescribed did
not match regimen
recommended by specialist
Continued first-line
regimen despite
recommendation for switch
Data
missing
Standard second-line ART* 324 247 (76.2) 17 (5.2) 39 (12.0) 21 (6.5)
Other standard
second-line ART†
41 22 (53.7) 9 (22.0) 8 (19.5) 2 (4.9)
Non-standard second
line ART‡
21 7 (33.3) 10 (47.6) 1 (4.8) 3 (14.3)
Non-standard
salvage regimen§
3 0 2 (66.7) 1 (33.3) 0
Continue first-line ART 49 39 (79.6) 10 (20.4) NA 0
Total 438 (100) 315 (71.9) 48 (11.0) 49 (11.2) 26 (5.9)
*Second-line regimen recommended by national guidelines in the absence of genotypic resistance testing (based on treatment history).
†Second-line regimen included in national guidelines but not the regimen that would have been prescribed based on treatment history.
‡Alternative second-line regimen incorporating only drugs in national guidelines (e.g. 3 nucleoside reverse-transcriptase inhibitors and protease inhibitor).
§Alternative regimen incorporating novel antiretroviral agents (e.g. raltegravir, etravirine).
Genotype 
Figure 3 Graphical display of antiretroviral history and viral load/CD4+ cell count measurements (Case example 1).
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(d4T), lamivudine (3TC) and nevirapine (NVP). She
had commenced treatment in April 2007 with baseline
CD4+ cell count of 176 cells/μL. There was an excellent
initial virological response to ART accompanied by
modest immune recovery. Low-level viral rebound was
then followed by high-level viraemia which persisted for
over 12 months without switch to second-line therapy
(Figure 4). She admitted that her adherence had lapsed
around the time of the deaths of two close family
members. Genotypic resistance test demonstrated
extensive drug resistance – in particular the Q151M
complex (Q151M+V75I + F116Y), K65R and M184V
which together confer high-level resistance to all
nucleoside/nucleotide reverse-transcriptase inhibitors.
As a standard second-line regimen would only contain a
single active drug (lopinavir/ritonavir (LPV/r), a request
was made for special access to raltegravir (RTG), to
form a regimen of RTG/3TC/LPV/r. This request was
approved by the provincial Department of Health and
she was commenced on this regimen in October
2012. After four months of this regimen, adherence
was excellent and viral load was <40 copies/ml.
The process evaluation revealed a number of systematic
challenges. We found that the generation of genotypes
was labour intensive and time consuming [18]. This con-
tributed substantially to the overall turnaround time and
required that patients be scheduled for follow up one
month after initial clinic visit. Whilst this month allowed
time for intensified adherence counselling, it might also
have provided opportunities for clinical progression and
disengagement from care. In the absence of our model,
patients with two consecutive viral loads > 1000 copies/ml
could have been switched to second-line therapy on their
first visit as per national guidelines, assuming that adher-
ence issues had already been addressed. It is possible that
the system might have adversely affected the clinical man-
agement of patients who had delayed switching, although
we have no direct evidence to support this. However, we
have shown that in over one quarter of patients a switch
to standard second line therapy might be inappropriate or
lead to suboptimal outcomes. In addition, medical officers
attended the majority of clinics on a regular basis so that
there were many opportunities for re-referral upon patients’
subsequent visits. Whilst access to non-standard second-
line regimens was possible through application to a provin-
cial specialist panel, this process also often gave rise to sub-
stantial delays. We also demonstrated how the second-line
regimen sometimes differed from that recommended by
the specialist clinician and this was most commonly due to
new information becoming available between genotyping
and time of treatment switch (e.g. discovery of kidney dis-
ease and contra-indication to tenofovir). This demonstrates
the need for clear communication channels so that advice
can be modified in light of additional information.
Aside from these issues, the model has produced major
successes in a challenging environment. A genotypic re-
sistance report was generated from more than 90% of all
specimens sent. The specialist HIV clinicians amended the
reports promptly and comprehensively so that patients in
rural clinics, usually served by one medical officer visiting
on a weekly or fortnightly basis, received input from ex-
perts in HIV clinical care, which also often went beyond
just the ART recommendation. This model also allowed
patients to be treated in the PHC setting and avoid travel-
ling to a reference centre in Durban (approximately 250
km) in order to receive drug resistance genotypic testing
and specialist support. This application of telemedicine
Genotype 
Figure 4 Graphical display of antiretroviral history and viral load/CD4+ cell count measurements (Case example 2).
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afforded convenience to both the specialist and the med-
ical officer and enabled advanced care of hundreds of pa-
tients in a relatively efficient manner. Whilst this has so
far involved paper-based reports, as the PHC clinics lack
computers and some have erratic electricity supply, there
would be potential in the future to develop the model fully
around electronic health (eHealth) and mobile health
(mHealth) technologies [25].
Of particular relevance to the replication of this model
in other contexts are the findings that the process oper-
ated more rapidly in the clinic than in the support camp
setting, and that rates of follow-up were not significantly
different between the two. This could imply that the
more natural of the two applications of the model, which
is more easily integrated into existing HIV clinics, is the
more efficient one, although whether or not this would
be the case outside of a research study under routine
clinical and laboratory systems remains to be seen. It
could alternatively be due largely to capacity limitations
and the large number of samples produced in bulk with
the support camp system may have overloaded the lab
and the specialist clinician. However, the support camp
system has additional benefits, such as the opportunity
for group counselling and education sessions and multi-
disciplinary input and whether or not these translate to
better clinical outcomes and cost-effectiveness is some-
thing that is being explored in additional analyses.
The resistance test reports served not only as tools for
clinical management but also for education and training.
Medical officers and nurses involved in the system were
able to learn about drug resistance patterns and their
management in an applied environment. More generally,
awareness of the problem of antiretroviral resistance and
of issues relating to prevention of drug resistance was
raised amongst medical officers, nurses, counsellors and
patients. However, the ongoing programme of work re-
lating to antiretroviral resistance in this area means that
medical expertise, resources and opportunities for train-
ing exist that might not elsewhere in decentralised pro-
grammes. There is therefore a need now to explore the
operational feasibility of resistance testing in different
programmatic settings and to determine the key require-
ments for successful implementation.
During the implementation of the intervention we en-
countered a number of problems which we attempted to
address as the model evolved. We now have a system
within which the processes are almost always success-
fully operationalised, enabling individualised manage-
ment of complex resistance cases, employing expert
consultation via telemedicine and utilising multidiscip-
linary referral as appropriate. The system raises aware-
ness amongst frontline health care workers of the
increasing threat of drug resistance and our aim is to
strengthen capacity within the public health system to
manage and monitor the delivery of ART. This model
also provides valuable real-time data for surveillance of
drug resistance which, through the use of SATuRN
RegaDB, provides a highly valuable tool for patient man-
agement, clinical training, research and surveillance to
inform policy making [10].
Conclusions
In this paper we have demonstrated the feasibility of a
HIV-TFC model in a large PHC ART programme. Given
the relatively high proportion of patients for whom stand-
ard second-line ART regimens might be suboptimal, it
seems that the public health approach to the management
of treatment failure and switch to second-line ART might
have some limitations in this setting. Resistance testing at
treatment failure is routine in the US and Europe, and has
recently been recommended in certain situations for
South Africa [7,8]. Here we have reported only on a single
programme and the fact that the system was implemented
as part of a research project with additional human and
other resources does somewhat limit the generalisability
of our findings. Implementation within the public health
systems of southern Africa would be a massive challenge
to clinical and laboratory systems and it is important that
further research is performed to explore the feasibility, im-
pact and cost-effectiveness of different implementation
models within public health systems.
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